View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Daud Bhatti
  • Daud Bhatti

Nasdaq 100 (NQ) Potential Support Area

  March 28, 2024 By  Short Term Elliott Wave view in Nasdaq 100 (NQ) suggests that pullback to 18011.3 ended wave 4. The Index has turned higher in wave 5. Internal subdivision of wave 5 is unfolding as a diagonal. Up from wave 4, wave (i) ended at 18106.75 and wave (ii) ended at 18044. Wave (iii) higher ended at 18289.25 and wave (iv) ended at 18263.25. Final leg wave (v) ended at 18381 which completed wave ((i)). Pullback in wave ((ii)) ended at 18053.25 as a zigzag. The Index then res...

 PRESS RELEASE

Gilat Awarded $5 Million Order from the US Department of Defense

Gilat Awarded $5 Million Order from the US Department of Defense Gilat to provide DKET 3421 terminals for easy-to-deploy transportable satcom network hubs PETAH TIKVA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that the US Department of Defense awarded another $5 million order to one of the company’s US-based subsidiaries, DataPath. This additional order is for DKET 3421 terminals, transportable satcom hubs that deliver the operational...

 PRESS RELEASE

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Fi...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company’s promising research platform for tumor-activated bispecific and cell engager molecules Reports additional Phase 2 data for XTX202, a tumor-activated, beta-gamma biased IL-2, supporting potential as combination therapy; plans to discontinue monotherapy development and evaluate collaboration op...

 PRESS RELEASE

Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spid...

Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spider Silk from Waste Plastics ANN ARBOR, Mich., March 28, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute ("RPI"). Researchers at RPI published a paper in Microbial Cell Factories outlining a new and novel method of creating spider silk protein from waste plastics. This project used a new strain of Pseudomonas bacteria capable of converting depolymerized p...

SSY Group Ltd: 1 director

A director at SSY Group Ltd bought 500,000 shares at 4.904HKD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Shimmick Corporation Announces Fourth Quarter and Fiscal Year 2023 Res...

Shimmick Corporation Announces Fourth Quarter and Fiscal Year 2023 Results Shimmick realized significant progress with 24% growth in Shimmick Projects, with gross margin of 7% IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Shimmick Corp. (NASDAQ: SHIM), a leading water infrastructure company, today announced financial results for the fiscal year ended December 29, 2023. Fiscal Year 2023 Highlights Completed Initial Public Offering in November 2023Reported revenue of $633 million, which includes $434 million of Shimmick Projects revenue, an increase of 24% for fiscal y...

 PRESS RELEASE

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial...

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024Dosing commenced in VLS-01 (oral transmucosal DMT) P...

 PRESS RELEASE

Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders

Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders Company Announcement, Helsinki, 28 March 2024 at 1 PM (EET) Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”), announces as follows regarding the resolutions that were adopted at its Annual General Meeting of Shareholders held today on 28 March 2024. 1 PRESENTATION OF THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS, RESULT OF THE FINANCIAL YEAR AND DISCHARGE FROM LIABILITY. The annual general meeting adopted the company’s financial statements, includ...

 PRESS RELEASE

Nexstim Oyj: varsinaisen yhtiökokouksen päätökset

Nexstim Oyj: varsinaisen yhtiökokouksen päätökset Yhtiötiedote, Helsinki, 28.3.2024 klo 13.00 (EET) Nexstim Oyj: varsinaisen yhtiökokouksen päätökset Nexstim Oyj (NXTMH:HEX) (”Nexstim” tai ”Yhtiö”) ilmoittaa tänään 28.3.2024 tehdyistä varsinaisen yhtiökokouksen päätöksistä seuraavasti: 1 TILINPÄÄTÖKSEN SEKÄ KONSERNITILINPÄÄTÖKSEN VAHVISTAMINEN, TILIKAUDEN TULOS JA VASTUUVAPAUDEN MYÖNTÄMINEN Yhtiökokous vahvisti yhtiön tilinpäätöksen konsernitilinpäätöksineen vuodelta 2023 ja päätti, ettei tilikaudelta 1.1.-31.12.2023 makseta osinkoa ja että tilikauden 1.1.-31.12.2023 tulos kirjataan ker...

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding Endeavour Mining plc28 March 2024 Notification of transaction by Persons Discharging Managerial Responsibilities 1Details of the person discharging managerial responsibilities / person closely associated NameSrinivasan Venkatakrishnan2Reason for the notification Position/statusChair3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameEndeavour Mining plc b)Legal Entity Identifier code (LEI)529900NI5MXQ91GHXR074Details of the transaction: a)Description of the financial instrument, type of instrumentOrd...

 PRESS RELEASE

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results an...

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments. Recent Developments Novel MNPR-101 Radiopharmaceutical Program targeting uPAR – Phase 1 dosimetry clinical trial to commence in the coming weeks MNPR-101-Zr Phase 1 dosimetry clinical trial has ...

 PRESS RELEASE

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend GREAT NECK, N.Y., March 28, 2024 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (NASDAQ: ) announced today that, in accordance with the board approved dividend declared on February 7, 2024, a cash dividend of $0.115 per share will be paid to all shareholders of record on April 10, 2024. The dividend will be paid on April 15, 2024. Contact: Assaf Ran, CEO (516) 444-3400

 PRESS RELEASE

Stran & Company Reports 28.7% Increase in Sales and Achieves Profitabi...

Stran & Company Reports 28.7% Increase in Sales and Achieves Profitability for the 2023 Fiscal Year Benefitting from Increased Operating Efficiency and Economies of Scale, Evidenced by 156% Year-Over-Year Increase in Operating Income for the Fourth Quarter of 2023 Reports Net Earnings of $883,000 for the Fourth Quarter of 2023 Conference call to be held today at 10:00 AM ET QUINCY, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional pro...

 PRESS RELEASE

Milestone Pharmaceuticals Announces Resubmission of New Drug Applicati...

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, the Company’s lead investigational product for the management of paroxysmal supraventricular...

 PRESS RELEASE

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activa...

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program -- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers -- FOSTER CITY, Calif. and WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage ...

 PRESS RELEASE

PyroGenesis Schedules 2023 Fiscal Year Financial Results and Business ...

PyroGenesis Schedules 2023 Fiscal Year Financial Results and Business Update Conference Call MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- PyroGenesis Canada Inc. () (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, today announces that it plans to host a conference call at 10:00 AM Eastern Time on Tuesday April 2, 2024, to discuss the Company’s financial r...

 PRESS RELEASE

Invivyd Reports Full Year 2023 Financial Results and Recent Business H...

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise PEMGARDA product availability in the U.S. anticipated imminentlyPEMGARDA is the first authorized mAb from Invivyd’s INVYMAB™ platform approach designed to address the challenge of rapid viral evolutionLeveraged INVYMAB platform approach to design VYD2311, the company’s next anticipated SAR...

 PRESS RELEASE

Troilus Provides Operational Update

Troilus Provides Operational Update MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5R) (“Troilus” or the “Company”), provides an operational update related to the advancement of its gold-copper Troilus Project (“Troilus” or the “Project”), located in northcentral Quebec; one of the largest undeveloped gold equivalent deposits in North America. Operational Update The Feasibility Study for the Troilus Project is proceeding well, as the various components of the report approach finalization to create a cohesive picture of the potential futu...

 PRESS RELEASE

Telesat Reports Results for the Quarter and Twelve Months Ended Decemb...

Telesat Reports Results for the Quarter and Twelve Months Ended December 31, 2023 OTTAWA, March 28, 2024 (GLOBE NEWSWIRE) -- (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three-month and one-year periods ended December 31, 2023. All amounts are in Canadian dollars and reported under International Financial Reporting Standards (IFRS) unless otherwise noted. “Telesat achieved a great deal in 2023 and I am pleased with our financial performance and, more importantly in terms of our futur...

 PRESS RELEASE

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Fin...

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWS...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch